HRCM
PCVX icon

Hood River Capital Management’s Vaxcyte PCVX Stock Holding History

Hood River Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-751,614
Closed -$28.4M – 168
2025
Q1 		$28.4M Buy
751,614
+350,172
+87% +$28M 0.48% 81
2024
Q4 		$32.9M Buy
+401,442
New +$39.9M 0.49% 81

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Hood River Capital Management's PCVX Position: Q2 2025 in Review

Hood River Capital Management sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 751,614 shares — an estimated $28.4M sold.

Hood River Capital Management first reported a position in PCVX in Q4 2024 and held it in 2 quarters. The position peaked at $32.9M in Q4 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Hood River Capital Management reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Hood River Capital Management sold 751,614 Vaxcyte shares in Q2 2025, an estimated $28.4M.
  • Hood River Capital Management first reported a position in Vaxcyte in Q4 2024 and held it in 2 quarters.
  • Hood River Capital Management's Vaxcyte position peaked at $32.9M in Q4 2024.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Hood River Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.